299 related articles for article (PubMed ID: 11244003)
1. Effect of N-acetyl-seryl-aspartyl-lysyl-proline on DNA and collagen synthesis in rat cardiac fibroblasts.
Rhaleb NE; Peng H; Harding P; Tayeh M; LaPointe MC; Carretero OA
Hypertension; 2001 Mar; 37(3):827-32. PubMed ID: 11244003
[TBL] [Abstract][Full Text] [Related]
2. N-Acetyl-seryl-aspartyl-lysyl-proline inhibits ET-1-induced collagen production by preserving Src homology 2-containing protein tyrosine phosphatase-2 activity in cardiac fibroblasts.
Peng H; Carretero OA; Peterson EL; Yang XP; Santra K; Rhaleb NE
Pflugers Arch; 2012 Oct; 464(4):415-23. PubMed ID: 22968858
[TBL] [Abstract][Full Text] [Related]
3. Antifibrotic effects of N-acetyl-seryl-aspartyl-Lysyl-proline on the heart and kidney in aldosterone-salt hypertensive rats.
Peng H; Carretero OA; Raij L; Yang F; Kapke A; Rhaleb NE
Hypertension; 2001 Feb; 37(2 Pt 2):794-800. PubMed ID: 11230375
[TBL] [Abstract][Full Text] [Related]
4. Antifibrotic effect of Ac-SDKP and angiotensin-converting enzyme inhibition in hypertension.
Rasoul S; Carretero OA; Peng H; Cavasin MA; Zhuo J; Sanchez-Mendoza A; Brigstock DR; Rhaleb NE
J Hypertens; 2004 Mar; 22(3):593-603. PubMed ID: 15076166
[TBL] [Abstract][Full Text] [Related]
5. Long-term effect of N-acetyl-seryl-aspartyl-lysyl-proline on left ventricular collagen deposition in rats with 2-kidney, 1-clip hypertension.
Rhaleb NE; Peng H; Yang XP; Liu YH; Mehta D; Ezan E; Carretero OA
Circulation; 2001 Jun; 103(25):3136-41. PubMed ID: 11425781
[TBL] [Abstract][Full Text] [Related]
6. Interaction of N-acetyl-seryl-aspartyl-lysyl-proline with the angiotensin-converting enzyme 2-angiotensin-(1-7)-Mas axis attenuates pulmonary fibrosis in silicotic rats.
Gao X; Xu H; Zhang B; Tao T; Liu Y; Xu D; Cai W; Wei Z; Li S; Zhang H; Mao N; Zhang G; Li D; Jin F; Li S; Zhang L; Liu H; Hao X; Yang F
Exp Physiol; 2019 Oct; 104(10):1562-1574. PubMed ID: 31290182
[TBL] [Abstract][Full Text] [Related]
7. N-acetyl-seryl-aspartyl-lysyl-proline mediates the anti-fibrotic properties of captopril in unilateral ureteric obstructed BALB/C mice.
Chan GCW; Wu HJ; Chan KW; Yiu WH; Zou A; Huang XR; Lan HY; Lai KN; Tang SCW
Nephrology (Carlton); 2018 Apr; 23(4):297-307. PubMed ID: 28075040
[TBL] [Abstract][Full Text] [Related]
8. Characterization and localization of Ac-SDKP receptor binding sites using 125I-labeled Hpp-Aca-SDKP in rat cardiac fibroblasts.
Zhuo JL; Carretero OA; Peng H; Li XC; Regoli D; Neugebauer W; Rhaleb NE
Am J Physiol Heart Circ Physiol; 2007 Feb; 292(2):H984-93. PubMed ID: 17028162
[TBL] [Abstract][Full Text] [Related]
9. High plasma level of N-acetyl-seryl-aspartyl-lysyl-proline: a new marker of chronic angiotensin-converting enzyme inhibition.
Azizi M; Ezan E; Nicolet L; Grognet JM; Ménard J
Hypertension; 1997 Nov; 30(5):1015-9. PubMed ID: 9369248
[TBL] [Abstract][Full Text] [Related]
10. Angiotensin-converting enzyme inhibitors: a new mechanism of action.
Peng H; Carretero OA; Vuljaj N; Liao TD; Motivala A; Peterson EL; Rhaleb NE
Circulation; 2005 Oct; 112(16):2436-45. PubMed ID: 16216963
[TBL] [Abstract][Full Text] [Related]
11. Acute angiotensin-converting enzyme inhibition increases the plasma level of the natural stem cell regulator N-acetyl-seryl-aspartyl-lysyl-proline.
Azizi M; Rousseau A; Ezan E; Guyene TT; Michelet S; Grognet JM; Lenfant M; Corvol P; Ménard J
J Clin Invest; 1996 Feb; 97(3):839-44. PubMed ID: 8609242
[TBL] [Abstract][Full Text] [Related]
12. Prevention of aortic fibrosis by N-acetyl-seryl-aspartyl-lysyl-proline in angiotensin II-induced hypertension.
Lin CX; Rhaleb NE; Yang XP; Liao TD; D'Ambrosio MA; Carretero OA
Am J Physiol Heart Circ Physiol; 2008 Sep; 295(3):H1253-H1261. PubMed ID: 18641275
[TBL] [Abstract][Full Text] [Related]
13. d-amino acid modification protects N-Acetyl-seryl-aspartyl-lysyl-proline from physiological hydroxylation and increases its antifibrotic effects on hepatic fibrosis.
Zhang X; Zhou J; Zhu Y; He L; Pang Z; Wang Z; Xu C; Zhang C; Hao Q; Li W; Zhang W; Zhang Y; Li M
IUBMB Life; 2019 Sep; 71(9):1302-1312. PubMed ID: 30900390
[TBL] [Abstract][Full Text] [Related]
14. Role of N-acetyl-seryl-aspartyl-lysyl-proline in the antifibrotic and anti-inflammatory effects of the angiotensin-converting enzyme inhibitor captopril in hypertension.
Peng H; Carretero OA; Liao TD; Peterson EL; Rhaleb NE
Hypertension; 2007 Mar; 49(3):695-703. PubMed ID: 17283252
[TBL] [Abstract][Full Text] [Related]
15. N-acetyl-seryl-aspartyl-lysyl-proline (Ac-SDKP): Potential target molecule in research of heart, kidney and brain.
Hrenak J; Paulis L; Simko F
Curr Pharm Des; 2015; 21(35):5135-43. PubMed ID: 26350537
[TBL] [Abstract][Full Text] [Related]
16. The anti-inflammatory peptide Ac-SDKP: Synthesis, role in ACE inhibition, and its therapeutic potential in hypertension and cardiovascular diseases.
Kumar N; Yin C
Pharmacol Res; 2018 Aug; 134():268-279. PubMed ID: 29990624
[TBL] [Abstract][Full Text] [Related]
17. Decreased endogenous levels of Ac-SDKP promote organ fibrosis.
Cavasin MA; Liao TD; Yang XP; Yang JJ; Carretero OA
Hypertension; 2007 Jul; 50(1):130-6. PubMed ID: 17470726
[TBL] [Abstract][Full Text] [Related]
18. Ac-SDKP reverses cardiac fibrosis in rats with renovascular hypertension.
Peng H; Carretero OA; Brigstock DR; Oja-Tebbe N; Rhaleb NE
Hypertension; 2003 Dec; 42(6):1164-70. PubMed ID: 14581293
[TBL] [Abstract][Full Text] [Related]
19. The Effects of Angiotensin Converting Enzyme Inhibitors (ACE-I) on Human N-Acetyl-Seryl-Aspartyl-Lysyl-Proline (Ac-SDKP) Levels: A Systematic Review and Meta-Analysis.
Mnguni AT; Engel ME; Borkum MS; Mayosi BM
PLoS One; 2015; 10(12):e0143338. PubMed ID: 26656271
[TBL] [Abstract][Full Text] [Related]
20. N-acetyl-seryl-aspartyl-lysyl-proline inhibits DNA synthesis in human mesangial cells via up-regulation of cell cycle modulators.
Kanasaki K; Haneda M; Sugimoto T; Shibuya K; Isono M; Isshiki K; Araki S; Uzu T; Kashiwagi A; Koya D
Biochem Biophys Res Commun; 2006 Apr; 342(3):758-65. PubMed ID: 16497271
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
